- Recent Funding
- Investors
- Arix Bioscience
Arix Bioscience portfolio
Arix Bioscience has 1 portfolio company on record at Recent Funding.
About this page
It is an investor based in London, GB, founded in 2015. Its most recent investment on record is Velosbio's $58M Series A round in October 2018, which it led, alongside Pappas Ventures, Takeda, Decheng Capital and 2 others. That company is in Health and bio.
About Arix Bioscience
What Arix Bioscience invests in
- Health and bio · 1 · 100%
How Arix Bioscience invests
| Stage | Deals | Capital in rounds |
|---|---|---|
| Series A | 1 100% | $58M |
Arix Bioscience portfolio companies
| Company | Round with Arix Bioscience | Total raised | Latest raise |
|---|---|---|---|
Health and bio |
Series A · $58M · lead | $58M | Aug 2, 2026 Series B+ |
Most frequent co-investors
DDecheng Capital1 shared round · last Oct 1, 2018
SSofinnova Partners1 shared round · last Oct 1, 2018
CChiesi Ventures1 shared round · last Oct 1, 2018
- PPappas Ventures1 shared round · last Oct 1, 2018
TTakeda1 shared round · last Oct 1, 2018
Similar investors
IIzou Partners2 companies · 2 deals in 12 mo
- TThe Ljungstrom Family Office2 companies · 2 deals in 12 mo
OO'Shaughnessy Ventures3 companies · 1 deal in 12 mo
SSide Stage Ventures3 companies
AAble Partners4 companies · 1 deal in 12 mo
BBdc Thrive venture5 companies · 3 deals in 12 mo
Investors whose portfolios on Recent Funding center on the same category (Health and bio).
How this is counted
Firm profile: Fundraising Fox Open Dataset v2026-11, CC BY 4.0. Track-record counts are theirs, not Recent Funding's.
Share is of the 1 round on Recent Funding that name Arix Bioscience. Rounds with no announced date are left out of the year split, and "round" is a round whose stage is not on file.
Portfolio companies are the companies on Recent Funding with a round that lists Arix Bioscience, which is a subset of its real portfolio. API: /api/v1/investors/arix-bioscience (get a free API key). More: the most active VC firms and new venture capital funds.